

Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

NCT07269249

Status	RECRUITING
Sponsor	National Cancer Institute, Naples
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (9)

- Signed informed consent form
- Age \geq 18 years
- Histologically confirmed stage II-III rectal cancer
- dMMR/MSI status assessed locally by Immunohistochemistry, next-generation sequencing or PCR
- For the retrospective part of the study:
... and 4 more (see full listing online)

Exclusion (4)

- \geq Distant metastasis
- Major cognitive dysfunction or psychiatric disorders
- Any previous systemic or local treatment for rectal cancer
- Dostarlimab received within an interventional clinical trial

Locations (2 total)

ASL Napoli 1, Presidio Ospedaliero Ospedale del mare, Oncologia medica, Naples, Italy
IRCCS Fondazione G. Pascale, Unità Operativa Complessa Oncologia Addominale, Naples, Italy